Effects of tea polyphenols on the expression of NF-κB, COX-2 and survivin in Lewis lung carcinoma xenografts in C57Bl/6 mice

Chinese Journal of Lung Cancer

Volumn 15, Issue 5, 2012, Pages 271-276

  Wang, Jing ^a,b   Chen, Xinyi ^a,b   Hou, Li ^a,b   Li, Li ^c   Lu, Hongfei ^a   Liu, Wei ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c WANGJING HOSPITAL   (China)

Author keywords

COX 2; Lung neoplasms; NF B; Survivin; Tea polyphenols

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYPHENOL; SURVIVIN; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TEA; TUMOR XENOGRAFT;

EID: 84992222948     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.05.04     Document Type: Article

References (12)

1. Xu L, Hou L, Liu J, et al. Tea polyphenols' effects on tumor inhibition rate of xenografted tumor in S180 mice. Zhonghua Zhong Yi Yao Za Zhi, 2005, 20(12): 718-720.
2. Chen XY, Zhang YM. Effect of tea polyphenols on expression of C-Jun in breast cancer. Xian Dai Sheng Wu Yi Xue Jin Zhan, 2007, 7(8): 1121-1123.
3. Wu HL, Chen XY, Han L, et al. Experiments of tea polyphenols' effects on human umbilical vein endothelial cell proliferation and apoptosis. Beijing Zhong Yi Yao, 2008, 27(4): 294-295.
4. Dai H, Ma CJ, Liu CY, et al. Pilot research on the combination of tea polyphenols and gefitinib inhibiting xenografted tumor growth of human lung adenocarcinoma. Xian Dai Sheng Wu Yi Xue Jin Zhan, 2009, 9(5): 801-806,828.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420(6917): 860-867.
6. He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol, 2007, 44(11): 2850-2859.
7. Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol, 2002, 2(10): 725-734.
8. Spano JP, Chouahnia K, Morere JF. Cyclooxygenase-2 inhibitors and lung carcinoma. Bull Cancer, 2004, 91(Suppl 2): 109-112.
9. Eliopoulos AG, Davies C, Blake SS, et al. The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-kappa B signaling downstream of TRAF2. J Virol, 2002, 76(9): 4567-4579.
10. Hugo C, Jason RF, Daniel RB, et al. Dissecting the role of endothelial Survivin deltaEx3 in angiogenesis. Blood, 2007, 109(4): 1479-1489.
11. Krysan K, Dalwadi H, Harma S, et al. Cyclooxygenase 2-dependent expression of surviving is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res, 2004, 64(18): 6359-6362.
12. Liang D, Song XQ. Thalidomide in treatment for lung cancer. Zhong Liu Xue Za Zhi, 2008, 14(4): 326-328.